Where does O6 -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?-Reference-Cited by-同舟云学术

Where does O6 -methylguanine DNA methyltransferase promoter methylation assessment place temozolomide in the future standards of care for glioblastoma?

Published:2018-01-30 Issue:7 Volume:124 Page:1316-1318
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Weller Michael¹

Affiliation:

1. Department of Neurology; University Hospital and University of Zurich; Zurich Switzerland

Funder

Actelion

Acceleron

Bayer

OGD2 Pharma

Piqur

Tragara

Abbvie

MSD

Merck

Novocure

Roche

Bristol-Myers Squibb

Celgene

Celldex

Orbus

Pfizer

Progenics

Teva

Tocagen

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference19 articles.

1. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine;Belanich;Cancer Res.,1996

2. Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: a Southwest Oncology Group study;Jaeckle;J Clin Oncol.,1998

3. DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma;Friedman;J Clin Oncol.,1998

4. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents;Esteller;N Engl J Med.,2000

5. Clinical trial substantiates the predictive value of O6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide;Hegi;Clin Cancer Res.,2004

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Temozolomide based treatment in glioblastoma: 6 vs. 12 months;Oncology Letters;2024-07-02

2. Zotiraciclib (TG02) for newly diagnosed glioblastoma in the elderly or for recurrent glioblastoma: The EORTC 1608 STEAM trial;European Journal of Cancer;2024-02

3. Updates in IDH-Wildtype Glioblastoma;Neurotherapeutics;2022-05-31

4. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial;Neuro-Oncology;2022-04-14

5. Isocitrate Dehydrogenase Wild-type Glial Tumors, Including Glioblastoma;Hematology/Oncology Clinics of North America;2022-02